Company Analysis
Sign in

Castle Biosciences, Inc. (CSTL)

Nasdaq: CSTL · Services-Medical Laboratories · Friendswood, TX · filing with the SEC since 2008
Full chart Alerts Compare
Grade6.1
◀ Past 5.6● Present 7.3▶ Future 5.1
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

16 patents granted to the 8 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Castle Biosciences, Inc.’s names, not what it holds today.

Patents granted
16
16 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 2 in 2024 and 2 in 2023
Applications published
30
5 of them in 2025
Names they are printed under
8
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Analysis of biological materials4
Biotechnology4
Computer technology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name8 counted
Castle Biosciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
13 published
CERNOSTICS, INC. a subsidiary
US, as the owner printed on each patent
7 granted
3 published
CASTLE BIOSCIENCES, INC. its own name
US, as the owner printed on each patent
6 granted
3 published
MYRIAD MYPATH, LLC a subsidiary
US, as the owner printed on each patent
3 granted
2 published
CERNOSTICS, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
ALTHEADX, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
MYRIAD MYPATH, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
Althea DX a subsidiary
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 14, 202512,442,819Methods of predicting progression of Barrett's esophagusAnalysis of biological materialsCERNOSTICS, INC.
Jul 29, 202512,372,527Systems and compositions for diagnosing Barrett's esophagus and methods of using the sameAnalysis of biological materialsCERNOSTICS, INC.
Jul 29, 202512,371,750Genes and gene signatures for diagnosis and treatment of melanomaComputer technologyMYRIAD MYPATH, LLC
Jul 22, 202512,365,948Diagnostic test for predicting metastasis and recurrence in cutaneous melanomaBiotechnologyCASTLE BIOSCIENCES, INC.
May 7, 202411,976,333Methods of diagnosing and treating patients with cutaneous squamous cell carcinomaBiotechnologyCASTLE BIOSCIENCES, INC.
May 7, 202411,976,331Methods of diagnosing and treating patients with cutaneous squamous cell carcinomaBiotechnologyCASTLE BIOSCIENCES, INC.
Dec 5, 202311,834,719Genes and gene signatures for diagnosis and treatement of melanomaComputer technologyMYRIAD MYPATH, LLC
Feb 21, 202311,584,967Genes and gene signatures for diagnosis and treatment of melanomaComputer technologyMYRIAD MYPATH, LLC
Sep 6, 202211,434,536Diagnostic test for predicting metastasis and recurrence in cutaneous melanomaBiotechnologyCASTLE BIOSCIENCES, INC.
Jan 11, 202211,221,333Systems and compositions for diagnosing Barrett's esophagus and methods of using the sameAnalysis of biological materialsCERNOSTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0305065DIAGNOSTIC TEST FOR PREDICTING METASTASIS AND RECURRENCE IN CUTANEOUS MELANOMABiotechnologyCastle Biosciences, Inc.
Jul 31, 20252025/0243552METHODS OF DIAGNOSING AND TREATING PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMABiotechnologyCastle Biosciences, Inc.
Jul 3, 20252025/0215507METHODS OF DIAGNOSING AND TREATING PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMABiotechnologyCastle Biosciences, Inc.
Jan 16, 20252025/0019768METHODS OF DIAGNOSING AND TREATING PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMABiotechnologyCastle Biosciences, Inc.
Jan 16, 20252025/0019767METHODS OF DIAGNOSING AND TREATING PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMABiotechnologyCastle Biosciences, Inc.
Jun 20, 20242024/0200145GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMAComputer technologyMYRIAD MYPATH, LLC · patent 12,371,750 granted from it
Oct 26, 20232023/0340615GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMAComputer technologyMYRIAD MYPATH, LLC
Mar 16, 20232023/0077559DIAGNOSTIC TEST FOR PREDICTING METASTASIS AND RECURRENCE IN CUTANEOUS MELANOMABiotechnologyCastle Biosciences, Inc. · patent 12,365,948 granted from it
Sep 15, 20222022/0291219SYSTEMS AND COMPOSITIONS FOR DIAGNOSING BARRETT'S ESOPHAGUS AND METHODS OF USING THE SAMEAnalysis of biological materialsCERNOSTICS, INC. · patent 12,372,527 granted from it
Sep 8, 20222022/0285032Determining Prognosis and Treatment based on Clinical-Pathologic Factors and Continuous Multigene-Expression Profile ScoresComputer technologyCASTLE BIOSCIENCES, INC.
What it applied for, 2024 to 2025: Biotechnology 5 · Computer technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CSTL · research, not advice